TR201715231A2 - The pharmaceutical combination comprising dapoxetine and phosphodiesterase type-5 - Google Patents

The pharmaceutical combination comprising dapoxetine and phosphodiesterase type-5 Download PDF

Info

Publication number
TR201715231A2
TR201715231A2 TR2017/15231A TR201715231A TR201715231A2 TR 201715231 A2 TR201715231 A2 TR 201715231A2 TR 2017/15231 A TR2017/15231 A TR 2017/15231A TR 201715231 A TR201715231 A TR 201715231A TR 201715231 A2 TR201715231 A2 TR 201715231A2
Authority
TR
Turkey
Prior art keywords
dapoxetine
pharmaceutical combination
phosphodiesterase type
polymorph
solvate
Prior art date
Application number
TR2017/15231A
Other languages
Turkish (tr)
Inventor
Güner Di̇cle
Palantöken Arzu
Türkyilmaz Ali̇
Original Assignee
Montero Gida Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Montero Gida Sanayi Ve Ticaret Anonim Sirketi filed Critical Montero Gida Sanayi Ve Ticaret Anonim Sirketi
Priority to TR2017/15231A priority Critical patent/TR201715231A2/en
Priority to EP18865578.1A priority patent/EP3694519A4/en
Priority to PCT/TR2018/050568 priority patent/WO2019074464A2/en
Publication of TR201715231A2 publication Critical patent/TR201715231A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds

Abstract

The present invention relates to pharmaceutical combination comprising dapoxetine or a pharmaceutically acceptable salt, solvate or polymorph thereof and a PDE5 inhibitor or a pharmaceutically acceptable salt, solvate or polymorph thereof having a release profile comprises both immediate release and modified release.
TR2017/15231A 2017-10-09 2017-10-09 The pharmaceutical combination comprising dapoxetine and phosphodiesterase type-5 TR201715231A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
TR2017/15231A TR201715231A2 (en) 2017-10-09 2017-10-09 The pharmaceutical combination comprising dapoxetine and phosphodiesterase type-5
EP18865578.1A EP3694519A4 (en) 2017-10-09 2018-10-08 The pharmaceutical combination comprising dapoxetine and phosphodiesterase type-5
PCT/TR2018/050568 WO2019074464A2 (en) 2017-10-09 2018-10-08 The pharmaceutical combination comprising dapoxetine and phosphodiesterase type-5

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2017/15231A TR201715231A2 (en) 2017-10-09 2017-10-09 The pharmaceutical combination comprising dapoxetine and phosphodiesterase type-5

Publications (1)

Publication Number Publication Date
TR201715231A2 true TR201715231A2 (en) 2019-04-22

Family

ID=66100099

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2017/15231A TR201715231A2 (en) 2017-10-09 2017-10-09 The pharmaceutical combination comprising dapoxetine and phosphodiesterase type-5

Country Status (3)

Country Link
EP (1) EP3694519A4 (en)
TR (1) TR201715231A2 (en)
WO (1) WO2019074464A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112263581A (en) * 2020-11-29 2021-01-26 长沙晶易医药科技有限公司 Double-layer tablet compound preparation for treating PE and ED and preparation method thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006038217A1 (en) * 2004-10-05 2006-04-13 Strides Acrolab Limited An improved drug delivery system of citalopram hydrobromide and process for producing the same
DE102005016981A1 (en) * 2005-04-13 2006-10-19 Bayer Healthcare Ag Combination therapy for benign prostatic hyperplasia
EP2316435A1 (en) * 2009-10-22 2011-05-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of PDE-5 inhibitors and dapoxetine
KR101465077B1 (en) * 2010-07-06 2014-11-26 주식회사 네비팜 Time-delayed sustained release pharmaceutical composition comprising dapoxetine for oral administration
US20150202168A1 (en) * 2012-08-17 2015-07-23 Sanovel llac Sanayi Ve Ticaret Anonim Sirketi Oral film formulations comprising dapoxetine and tadalafil
US20150216798A1 (en) * 2012-08-17 2015-08-06 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Novel orally administered pharmaceutical formulations
CN103550775B (en) * 2013-10-18 2017-08-25 广州共禾医药科技有限公司 A kind of anti-insomnia composition and its application and the multiphase pulse prepared using said composition understand suddenly preparation and preparation method thereof
CN106727439A (en) * 2016-12-21 2017-05-31 河南中帅医药科技股份有限公司 A kind of memantine is sustained donepezil quick-release compound capsule
TR201620151A2 (en) * 2016-12-30 2018-07-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING TADALAFIL AND DAPOXETIN

Also Published As

Publication number Publication date
WO2019074464A2 (en) 2019-04-18
WO2019074464A3 (en) 2019-05-31
EP3694519A2 (en) 2020-08-19
EP3694519A4 (en) 2021-10-20

Similar Documents

Publication Publication Date Title
MY197700A (en) Compounds useful for inhibiting cdk7
EP3687543A4 (en) Combination pharmaceutical agents as rsv inhibitors
EP3601285A4 (en) Therapeutic agent for phosphodiesterase inhibition and its related disorders
SG11202104687SA (en) Ret inhibitors, pharmaceutical compositions and uses thereof
GB2589575B (en) Pupil expander
EP3741374A4 (en) Mtor inhibitor, pharmaceutical composition and use thereof
EP3833350A4 (en) Pyrrolopyrimidine itk inhibitors
GB2589583B (en) Pupil expander
HK1244704A1 (en) Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof
EP3327014A4 (en) Egfr inhibitor and pharmaceutically acceptable salt and polymorph thereof, and use thereof
SG11202104686QA (en) Ret inhibitors, pharmaceutical compositions and uses thereof
MX2017016802A (en) Pharmaceutical formulations.
EP3802562A4 (en) New pharmaceutical use
MX2022013274A (en) Fused triazolo-pyrimidine compounds having useful pharmaceutical application.
EP3856174A4 (en) Hdac1,2 inhibitors
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
WO2019074464A3 (en) The pharmaceutical combination comprising dapoxetine and phosphodiesterase type-5
EP3723743A4 (en) The pharmaceutical combination comprising dapoxetine, phosphodiesterase type-5 inhibitor and anti-emetic agent
IL282999A (en) 1,3,4-oxadiazolone compound and pharmaceutical
EP3988100A4 (en) Adenosine compound, pharmaceutically acceptable salt or stereoisomeride thereof, and use
EP3858355A4 (en) Anti-neurodegenerative disease agent
WO2019203746A3 (en) The pharmaceutical combination comprising raloxifene and aripiprazole
WO2019203748A3 (en) The composition comprising raloxifene with at least one antipsychotic agent
GB202113078D0 (en) New pharmaceutical use
GB201917327D0 (en) New pharmaceutical use